We also show that SCCHN is dependent on both BCL-XL and MCL-1 for survival, which can be efficiently targeted to induce marked apoptosis and tumor shrinkage, suggesting that a combination BH3 mimetic therapy may offer significant benefits in SCCHN. The gene discussed is MCL1; the disease is neoplasm.